The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder

Abstract

Possible effects of the atypical antipsychotic aripiprazole on the pharmacokinetics of standard antidepressant therapies (ADTs) were assessed in two open-label, non-randomised studies in healthy subjects (Studies 1 and 2) and two placebo-controlled studies in patients with major depressive disorder (MDD) (Studies 3 and 4). Healthy subjects received venlafaxine 75 mg/day (Study 1; N = 38) or escitalopram 10 mg/ day (Study 2; N = 25) with the addition of aripiprazole 10—20 mg/day (10 mg/day fixed dose in Study 2) for 14 days. Patients with MDD (N = 498; Studies 3 and 4) received escitalopram (10—20 mg/day), fluoxetine (20—40 mg/day), paroxetine controlled-release (37.5—50 mg/day), sertraline (100—150 mg/day) or venlafaxine extended-release (150—225 mg/day) for 8 weeks plus placebo. Incomplete responders were randomised (1:1) to placebo or adjunctive aripiprazole 2—20 mg/day. Blood samples were collected for pharmacokinetic analysis of ADTs. Plasma concentration—time data from Studies 3 and 4 were combined for statistical analysis. In healthy subjects, point estimates [90% CI] for the ratios of geometric means of C_max (venlafaxine 1.148 [1.083—1.217]; escitalopram 1.04 [0.99—1.09]) and AUC_TAU (venlafaxine 1.183 [1.130—1.238]; escitalopram 1.07 [1.04—1.11]) indicated no meaningful increase in ADT exposure in the presence of aripiprazole. In patients, point estimates for mean plasma concentration ratios indicated no substantial effect of aripiprazole on any ADT escitalopram 0.970 [0.911—1.033], fluoxetine 1.177 [1.049—1.321], paroxetine 0.730 [0.598—0.892], sertraline 0.958 [0.887—1.035] or venlafaxine 0.966 [0.887—1.051]. Aripiprazole had no meaningful effects on the pharmacokinetics of standard ADTs in either healthy subjects or patients with MDD.

Keywords

antidepressants aripiprazole healthy subjects major depressive disorder pharmacokinetics

Get full access to this article

View all access options for this article.

References

Adson, DE , Kushner, MG , Fahnhorst, TA ( 2005) Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors . J Affect Disord 86: 99-104.

Barbee, JG , Conrad, EJ , Jamhour, NJ ( 2004a) Aripiprazole augmentation in treatment-resistant depression . Ann Clin Psychiatry 16: 189-194.

Barbee, JG , Conrad, EJ , Jamhour, NJ ( 2004b) The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 65: 975-981.

Berman, RM , Marcus, RN , Swanink, R. , McQuade, RD , Carson, WH , Corey-Lisle, PK , et al. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 843-853.

Bristol-Myers Squibb Company / Otsuka America Pharmaceutical Inc (2006) Aripiprazole (Abilify) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Co and Otsuka America Pharmaceutical, Inc.

Burris, KD , Molski, TF , Xu, C. , Ryan, E. , Tottori, K. , Kikuchi, T. , et al. (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381-389.

DeBattista, C. ( 2006) Augmentation and combination strategies for depression . J Psychopharmacol 20: 11-18.

DeLeon, A. , Patel, NC , Crismon, ML ( 2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26: 649-666.

Fava, GA , Ruini, C. , Belaise, C. ( 2007) The concept of recovery in major depression. Psychol Med 37: 307-317.

10.

Fogelman, SM , Schmider, J. , Venkatakrishnan, K. , von Moltke, LL , Harmatz, JS , Shader, RI , et al. (1999) O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20: 480-490.

11.

Hemeryck, A. , Belpaire, FM ( 2002) Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 3: 13-37.

12.

Hiemke, C. , Hartter, S. ( 2000) Pharmacokinetics of selective serotonin reuptake inhibitors . Pharmacol Ther 85: 11-28.

13.

Jordan, S. , Koprivica, V. , Chen, R. , Tottori, K. , Kikuchi, T. , Altar, CA ( 2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441: 137-140.

14.

Kobayashi, K. , Ishizuka, T. , Shimada, N. , Yoshimura, Y. , Kamijima, K. , Chiba, K. ( 1999) Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 27: 763-766.

15.

Lacey, LF , Keene, ON , Pritchard, JF , Bye, A. ( 1997) Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed. J Biopharm Stat 7: 171-178.

16.

Mallikaarjun, S. , Salazar, DE , Bramer, SL ( 2004) Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44: 179-187.

17.

Marcus, RN , McQuade, RD , Carson, WH , Hennicken, D. , et al. (2008) The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacol 28: 156-165.

18.

Pae, CU , Patkar, AA , Jun, TY , Lee, C. , Masand, PS , Paik, IH ( 2007) Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety 24: 522-526.

19.

Papakostas, GI , Petersen, TJ , Kinrys, G. , Burns, AM , Worthington, JJ , Alpert, JE , et al. (2005) Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 66: 1326-1330.

20.

Patkar, AA , Peindl, K. , Mago, R. , Mannelli, P. , Masand, PS ( 2006) An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 8: 82-87.

21.

Preskorn, SH ( 1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32(Suppl. 1): S1-S21.

22.

Rao, N. ( 2007) The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 46: 281-290.

23.

Rush, AJ , Trivedi, MH , Wisniewski, SR , Nierenberg, AA , Stewart, JW , Warden, D. , et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917.

24.

Shapiro, DA , Renock, S. , Arrington, E. , Chiodo, LA , Liu, LX , Sibley, DR , et al. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400-1411.

25.

Simon, JS , Nemeroff, CB ( 2005) Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder . J Clin Psychiatry 66: 1216-1220.

26.

Sogaard, B. , Mengel, H. , Rao, N. , Larsen, F. ( 2005) The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 45: 1400-1406.

27.

Spina, E. , de Leon, J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100: 4-22.

28.

Stark, AD , Jordan, S. , Allers, KA , Bertekap, RL , Chen, R. , Mistry Kannan, T. , et al. (2007) Interaction of the novel antipsychotic aripiprazole with 5-HT(1A) and 5-HT (2A) receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology ( Berl) 190: 373-382.

29.

Swainston Harrison, T. , Perry, CM ( 2004) Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64: 1715- 1736.

30.

Trivedi, MH , Fava, M. , Wisniewski, SR , Thase, ME , Quitkin, F. , Warden, D. , et al. (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354: 1243-1252.

31.

Worthington, JJ , Kinrys, G. , Wygant, LE , Pollack, MH ( 2005) Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 20: 9-11.